Company intelligence / Profile preview

Metabomed

Yavne, Center District, Israelmetabomed.com ↗
Ownership
Private
Employees
~10
Development stage
Other
01

Overview

Studies showed that a first-generation compound was active in patient-derived xenograft models with high ACSS2 expression, including as a single agent in colorectal and triple negative breast cancers, and in combination with platinum in gastric, ovarian, and non-small cell lung cancers[2]

Therapeutic areas
Oncology
Modalities
Small molecules
Industry
Biotech

Beyond the preview

Go deeper on Metabomed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Metabomed.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call